HER2-Positive Metastatic Breast Cancer: New Standard of CareHER2-Positive Metastatic Breast Cancer: New Standard of Care
Combining two targeted agents, trastuzumab and pertuzumab, with docetaxel resulted in unprecedented survival in HER2-positive metastatic breast cancer. Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Docetaxel | Health | Hematology | HER2 | Herceptin | Taxotere